The FDA is Developing, Approving, and Expediting Exciting New Therapies
source: pixabay.com

The FDA is Developing, Approving, and Expediting Exciting New Therapies

  Janet Woodcock, Director of the FDA’s Center for Drug Evaluation and Research (CDER) recently gave an interview to the publication FDA Voices about the agency’s approval in 2019 of a…

Continue Reading The FDA is Developing, Approving, and Expediting Exciting New Therapies

The FDA Has Just Approved the Very First Therapy for Erythropoietic Protoporphyria

EPP Erythropoietic protoporphyria (EPP) is a rare disease that causes extreme light sensitivity. This sensitivity is so extreme that being outside is extremely difficult for patients and many only come…

Continue Reading The FDA Has Just Approved the Very First Therapy for Erythropoietic Protoporphyria
Close Menu